GLAXOSMITHKLINE PLC Form 6-K January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

b) Position/status Chief Executive Officer

c) Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends

b) Nature of the transaction paid to shareholders on 12

January 2017.

Price(s) Volume(s)

c) Price(s) and volume(s)

£15.7149 27.773

Aggregated information n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status **CEO** Designate

c) Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence a) Description of the financial instrument each ('Ordinary Shares') ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 12 January 2017. Price(s) Volume(s) c) Price(s) and volume(s) £15.7149 0.005 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-01-12 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') Mr R G Connor a) Name President, Global b) Position/status Manufacturing & Supply c) Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction

a) Name GlaxoSmithKline plc

platform, auctioneer or auction monitor

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 12

January 2017.

Price(s) Volume(s)

c) Price(s) and volume(s)

£15.7149 33.594

Aggregated information n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

b) Position/status President, Global Vaccines

c) Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		£15.7149	707.341		
d)	Aggregated information	n/a (single transaction)			
	Aggregated volume Price				
e)	Date of the transaction	2017-01-12			
f)	Place of the transaction	London Stock Exchange (XLON)			
1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Mr S Dingemans			
b)	Position/status	Chief Financial Officer			
c)	Initial notification/ amendment	Initial notific	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary sha each ('Ordin ISIN: GB000	•		
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		£15.7149	121.722		

Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-01-12 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') Mr S A Hussain a) Name President, Global b) Position/status Pharmaceuticals c) Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence a) Description of the financial instrument each ('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares following the b) Nature of the transaction re-investment of dividends paid to shareholders on 12 January 2017. Price(s) Volume(s) c) Price(s) and volume(s) £15.7149 646.179 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-01-12

f) Place of the transaction

London Stock Exchange (XLON)

a)	Name	Mr D S Redfern			
b)	Position/status	Chief Strategy Officer			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')			

1. Details of PDMR/person closely associated with them ('PCA')

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12

ISIN: GB0009252882

January 2017.

Price(s) Volume(s)

c) Price(s) and volume(s)

d)

b) Nature of the transaction

£15.7149 1,010.257

Aggregated information

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, HR

c) Initial notification/

Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12

January 2017.

Price(s) Volume(s)

c) Price(s) and volume(s)

d)

b) Nature of the transaction

£15.7149 140.220

Aggregated information

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr P C Thomson a) Name

SVP, Communications & b) Position/status

Government Affairs

c) Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the

re-investment of dividends

paid to shareholders on 12

January 2017.

Price(s) Volume(s)

c) Price(s) and volume(s)

b) Nature of the transaction

£15.7149 453.092

Aggregated information d)

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr M M Slaoui

b) Position/status Chairman, Global Vaccines

c) Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		£15.7149	2.088		
d)	Aggregated information	n/a (single transaction)			
	Aggregated volume Price				
e)	Date of the transaction	2017-01-12			
f)	Place of the transaction	London Stock Exchange (XLON)			
1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Dr P J T Vallance			
b)	Position/status	President, R&D			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882			
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		£15.7149	1,693.943		

Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-01-12 f) Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') Mrs K Thomson a) Name PCA of Mr P C Thomson (SVP, Communications & b) Position/status Government Affairs) c) Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence a) Description of the financial instrument each ('Ordinary Shares') ISIN: GB000925288 Acquisition of Ordinary Shares following the b) Nature of the transaction re-investment of dividends paid to shareholders on 12 January 2017. Volume(s) Price(s) c) Price(s) and volume(s) £15.7149 111.130 Aggregated information n/a (single transaction) d) Aggregated volume Price e) Date of the transaction 2017-01-12

f) Place of the transaction

London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: January 16, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc